Healthtech VC firm Nina Capital announces five more investments, launches second fund set to reach €40m

Healthtech VC firm Nina Capital announces five more investments, launches second fund set to reach €40m

Published: 28-07-2021 14:52:00 | By: Pie Kamau | hits: 4002 | Tags:

Nina Capital, a specialized venture capital (VC) firm focused on health technology, announced its last five investments of its first fund and the launch of its second fund, Nina Capital Fund II FCRE, with an investment goal of €40 million, or approximately $47.4 million.

Nina Capital was founded in 2019 with its inaugural fund, Nina Capital Fund I FCRE, which reached its maximum size of €18 million ($21.3 million). In less than two years, Nina Capital has created an international portfolio of 23 companies in the U.S., Canada, and 11 European countries. To date, the firm has analyzed more than 2,000 health tech companies in pre-seed, seed, and Series A stages.

Marta-Gaia Zanchi, Founder and Managing Partner, Nina Capital: "This second fund is a natural continuation of our first, building on our geographical footprint and large, strategic flow of investment opportunities at the intersection of healthcare and technology. We are a purpose-built team with the necessary complementary expertise in healthcare, technology, and finance, applying the principles of need-driven investing to identify the best healthtech startups in their earliest stages of development, regardless of where they are, but with strong conviction that Europe is poised as a unique foundational ground for the next wave of breakout companies." 

Nina Capital Fund II FCRE will maintain the firm's focus of investing in health technology companies in the pre-seed and seed investment stages with the capacity to reach Series A. As its predecessor fund, Nina Capital Fund II FCRE will target need-driven businesses that deliver innovative and highly scalable solutions built to address the pain points of providers and other healthcare organizations. The value-based process of new venture creation known as Biodesign, born at Stanford University, remains core to the firm's investment approach.

Marc Subirats, Partner, Nina Capital: "The quality of startups in Europe is much higher than it once was. Our ambitions are international, and our network is strong in Europe, the U.S., Canada and Israel. We expect our companies to have equally broad geographical ambitions, coupled with the deep understanding of healthcare industry needs, a strong evidence-based approach, and compelling health economics."

The firm expects to hold a first closing for its newly registered fund in the fall. "We have the excellent support of our existing investor base, plus new investors who have taken notice of our ability to seek, find, and serve the right design-minded and cross-disciplinary founders," said Dr. Zanchi. Nina Capital Fund II FCRE is expanding its investor base with funds from other investment firms, international family offices, as well as individual investors with finance, management, and healthcare backgrounds."

www.nina.capital